 |
|
|
| |
Sofosbuvir/Velpatasvir for 12 Weeks in Genotype 1-4 HCV-Infected Liver Transplant Recipients
|
| |
| |
Reported by Jules Levin
AASLD: The Liver Meeting® 2017, October 20-24, 2017, Washington, DC
Kosh Agarwal,1 Lluis Castells,2 Beat Mullhaupt,3 William M.C. Rosenberg,4 Brian McNabb,5 Sarah Arterburn,5 Gregory Camus,5
John McNally,5 Diana M. Brainard,5 G. Mani Subramanian,5 Enoka Gonsalkorala,1 Maria Londoño,6 Jean-François Dufour,7 Xavier Forns6
1Kings College Hospital NHS Trust Foundation, London, UK; 2Hospital Universitari Vall d'Hebron, Centro de Investigacion Biomedica en Red de Enfermedades Hepáticas y Digestivas, Barcelona, Spain; 3University Hospital Zurich, Switzerland; 4UCL Institute for Liver and Digestive Health, London, UK;
5Gilead Sciences, Inc, Foster City, CA; 6Hospital Clínic de Barcelona, Centro de Investigacion Biomedica en Red de Enfermedades Hepáticas y Digestivas and Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain; 7Universität Bern, Switzerland
|
| |
|
|
|
|
|
